UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 28,
2022
Ocuphire Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-34079
|
|
11-3516358
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
37000 Grand River Avenue, Suite 120
Farmington Hills, MI
|
|
|
|
48335
|
|
(Address of
principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(248) 681-9815
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each
exchange on which registered
|
|
Common Stock,
$0.0001 par value
|
OCUP
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company
☐ |
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
On April 28, 2022, the Company issued a press release regarding the
results of its MIRA-4 pediatric safety trial for reversal of
mydriasis. A copy of the press release is filed as Exhibit 99.1 to
this Current Report on Form 8-K and incorporated herein by
reference.
Information contained on or accessible through any website
reference in the press release is not part of, or incorporated by
reference in, this Current Report on Form 8-K, and the inclusion of
such website addresses in this Current Report on Form 8-K by
incorporation by reference of the press release is as inactive
textual references only.
|
Item 9.01 |
Financial
Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
|
|
|
|
|
Press Release, dated April 28,
2022
|
|
104
|
|
Cover Page Interactive Data File
(embedded within Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
OCUPHIRE PHARMA,
INC.
|
|
|
|
|
|
|
By:
|
|
|
|
|
Mina Sooch
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
Date: April 28, 2022
|
|
|